GlassScriptPhysician profile
Candace Lewis
NPI 1912319781
$7,231.29
in general payments reported to CMS, 2019-2025
50 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,338 · 2022: $1,387 · 2023: $1,488 · 2024: $1,346 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.80 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.60 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $726.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $706.56 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $639.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $631.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $512.68 | 2021-2025 | |
| Astellas Pharma US INC | $254.60 | 2021-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $220.36 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.79 | 2021-2024 | Xifaxan, Trulance |
| Amgen INC. | $184.76 | 2022-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $166.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $164.26 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $153.61 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $135.81 | 2021 | |
| Alnylam Pharmaceuticals INC. | $124.80 | 2025 | Amvuttra |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.